PMID- 1723373
OWN - NLM
STAT- MEDLINE
DCOM- 19920309
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 42
IP  - 5
DP  - 1991 Nov
TI  - Treatment of Wilms' tumour. Current recommendations.
PG  - 766-80
AB  - Wilms' tumour (nephroblastoma, renal embryoma) is the fifth most common 
      paediatric malignancy, arising from the embryonal tissue of kidneys and first 
      formally described by Max Wilms in his classic 1899 monograph. Until the early 
      part of this century, Wilms' tumour was associated with a less than 20% survival 
      rate. The current survival rate exceeds 80%, primarily due to large 
      multi-institutional trials such as the National Wilms' Tumor Study (NWTS). These 
      studies have refined and defined the roles of surgery, chemotherapy, and 
      radiation in treating Wilms' tumour, based on staging and histology. The dramatic 
      improvement in the prognosis for children with Wilms' tumour, especially over the 
      past 20 years, represents a landmark achievement in the history of paediatric 
      oncology. Specific treatment recommendations are based on the current National 
      Wilms' Tumor Study IV schema. Stages I and II favourable histology patients do 
      not receive radiotherapy, but are treated postoperatively with 'pulsed' or 
      'conventional' dactinomycin and vincristine; stage III favourable histology 
      requires postoperative abdominal radiotherapy followed by triple agent, 
      'conventional' or 'pulsed' chemotherapy (dactinomycin, doxorubicin and 
      vincristine). Patients with stage IV favourable histology, stages II to IV 
      anaplastic, clear cell or rhabdoid histology, are treated similarly with 
      aggressive triple-agent chemotherapy, with the addition of radiotherapy to 
      selected sites. Recurrent and adult Wilms' tumours have poor prognoses and are 
      treated with aggressive surgery, radiotherapy and chemotherapy.
FAU - Mehta, M P
AU  - Mehta MP
AD  - University of Wisconsin Hospitals and Clinics, Madison.
FAU - Bastin, K T
AU  - Bastin KT
FAU - Wiersma, S R
AU  - Wiersma SR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 1CC1JFE158 (Dactinomycin)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Child
MH  - Child, Preschool
MH  - Dactinomycin/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Humans
MH  - Kidney Neoplasms/drug therapy/pathology/*therapy
MH  - Vincristine/administration & dosage
MH  - Wilms Tumor/drug therapy/pathology/*therapy
RF  - 59
EDAT- 1991/11/01 00:00
MHDA- 1991/11/01 00:01
CRDT- 1991/11/01 00:00
PHST- 1991/11/01 00:00 [pubmed]
PHST- 1991/11/01 00:01 [medline]
PHST- 1991/11/01 00:00 [entrez]
AID - 10.2165/00003495-199142050-00004 [doi]
PST - ppublish
SO  - Drugs. 1991 Nov;42(5):766-80. doi: 10.2165/00003495-199142050-00004.